Logo

Curacle Signs a License and Collaboration Agreement with Théa for Development and Commercialization of CU06-RE to treat Diabetic Macular Edema and Wet-AMD

Share this

Curacle Signs a License and Collaboration Agreement with Théa for Development and Commercialization of CU06-RE to treat Diabetic Macular Edema and Wet-AMD

Shots:

  • Curacle to receive a total of ~$2B including $6M up front & is eligible to receive ~$157.5M as development, regulatory and sales milestones along with royalties on sales upon the successful development of CU06-RE. The companies will closely collaborate on the clinical development of the product
  • Curacle will hold the marketing rights in all Asia countries & will lead the P-I & II clinical studies with TOI to provide both financial and infrastructure support while Théa will get the marketing rights in all other countries globally
  • The focus of the collaboration is to provide a new treatment with an alternative and non-invasive RoA for patients

 ­  Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions